| abstract |
The uses of pegylated interferon-alfa, alone, and in association with annanti-HIV-1 drug therapy, and ribavirin for the preparation of a medicament forntreating treatment-naive as well as treatment-experienced adult and pediatricnpatients having HIV-1 infections as well as patients co-infected with HIV-1 andnHCV involving comprising a therapeutically effective amount of pegylatedninterferon-alfa, e.g. , pegylated interferon alfa-2b as monotherapy or preferably innassociation with a therapeutically effective amount of at least one of ribavirin, IL-2,nIL-12, pentafuside alone or in combination with a therapeutically effectivenamount of an anti-HIV-1 drug therapy, e.g., HAART are disclosed. |